P046 HISTOLOGIC MEASURES OF MUCOSAL HEALING CORRELATE WITH ENDOSCOPIC MEASURES OF DISEASE ACTIVITY AT BASELINE AND FOLLOWING INDUCTION THERAPY WITH THE JANUS KINASE 1 INHIBITOR FILGOTINIB IN ACTIVE CROHN’S DISEASE: RESULTS FROM FITZROY STUDY

Filgotinib (fil), a selective JAK1 inhibitor, has shown efficacy in a randomized double-blind, placebo (pbo)-controlled phase 2 study in Crohn’s disease (CD) (FITZROY [1]), which included centrally read endoscopy and histopathology assessments after 10-week induction treatment.